Tag: test

Take the best free IQ test online with instant results at RealIQ.Online - a science-based, accurate, and trusted platform used by millions for reliable intelligence assessment.

Baltimore, MD, Aug. 02, 2025 (GLOBE NEWSWIRE) -- A presentation featuring James Altucher examines the engineering and technological breakthroughs behind Elon Musk’s Starlink project, highlighting how satellite architecture and hardware innovation could redefine global internet access.

As consumer demand for clean beauty and functional supplements rises in 2025, marine collagen gummies like Pilly Labs are emerging as a preferred daily solution for supporting skin texture, joint mobility, and hair strength — all without powders, pills, or synthetic additives.

As consumers search for natural alternatives to support focus, immune resilience, and metabolic balance, mushroom gummies are rapidly emerging as a preferred delivery method—especially in 2025’s ingredient-first supplement movement led by fruiting body extracts like Chaga, Lion’s Mane, and Cordyceps.

IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States.

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lockheed Martin Corporation (NYSE: LMT) securities between January 23, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), have until September 26, 2025 to seek appointment as lead plaintiff of the Lockheed Martin class action lawsuit. Captioned Khan v. Lockheed Martin Corporation, No. 25-cv-06197 (S.D.N.Y.), the Lockheed Martin class action lawsuit charges Lockheed Martin and certain of Lockheed Martin’s top current and former executives with violations of the Securities Exchange Act of 1934.

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.